Genomic pofiling associated with recurrence in patients with rectal cancer treated with chemoradiation

Pharmacogenomics

Volumn 7, Issue 1, 2006, Pages 67-88

  Gordon, Michael A ^a   Gil, Ji ^a   Lu, Bo ^a   Zhang, Wu ^a   Yang, Dongyun ^a   Yun, Jim ^a   Schneider, Sylke ^a   Groshen, Susan ^a   Iqbal, Syma ^a   Press, Oliver A ^a   Rhodes, Katrin ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Chemoradiation; Polymophism; Profiling; Rectal; Recurrence

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; X RAY REPAIR CROSS COMPLEMENTING PROTEIN 3; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CELL CYCLE REGULATION; CLASSIFICATION; CONTROLLED STUDY; DNA FINGERPRINTING; DNA REPAIR; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; POLYMERASE CHAIN REACTION; PREDICTION; RECTUM CANCER; RECURRENCE RISK; REGRESSION ANALYSIS; RISK ASSESSMENT; VALIDATION STUDY; CELL CYCLE; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PREDICTION AND FORECASTING; RECTUM TUMOR; RECURRENT DISEASE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; DISEASE PROGRESSION; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INTERLEUKIN-8; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RECTAL NEOPLASMS; RECURRENCE; TRANSFORMING GROWTH FACTOR BETA;

EID: 33644874012     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.1.67     Document Type: Article

References (51)

1. Jemal A, Murray T, Ward E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Douglass HO Jr, Moertel CG, Mayer RJ et al.: Survival after postoperative combination treatment of rectal cancer. N. Engl. J. Med. 315, 1294-1295 (1986).
3. Krook JE, Moertel CG, Gunderson LL et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324, 709-715 (1991).
4. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65-70 (2001).
5. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Nebert DW: Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271 (1997).
7. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91(2), 344-354 (2004).
8. Balasubramanian SP, Brown NJ, Reed MWR: Role of genetic polymorphisms in turnout angiogenesis. Br. J. Cancer 87, 1057-1065 (2002).
9. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6), 15-18 (2002).
10. Gorski DH, Beckett MA, Jaskowiak NT et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
11. Mauceri HJ, Hanna NN, Wayne JD et al.: Tumor necrosis factor α (TAT-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56, 4311-4314 (1996).
12. Mauceri HJ, Hanna NN, Beckett MA et al.: Combined effects of angiostatin and Ionizing radiation in antitumour therapy. Nature 394, 287-291 (1998).
13. Yuan A, Yang PC, Yu CJ et al.: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 162, 1957-1963 (2000).
14. Ueda T, Shimada E, Urikawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogeneous metastasis. J. Gastroenterol. 29, 423-429 (1994).
15. Edelman GM: Morphoregulatory molecules. Biochemistry 27, 3533-3543 (1988).
16. Ruoslahti E: Fibronectin and its receptors. Ann. Rev. Biochem. 57, 375-413 (1988).
17. Maurer CA, Friess H, Kretschmann B et al.: Overexpression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int. J. Cancer (Pred. Oncol.) 79, 76-81 (1998).
18. Eberhart CE, Coffey RJ, Radhika A et al.: Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroentology 107, 1183-1188 (1994).
19. 388 allele. Cancer Res. 62, 840-847 (2002).
20. Tepper JE, O'Conell M, Niedzwiecki D et al.: Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control - final report of intergroup 0114. J. Clin. Oncol. 20, 1744-1750 (2002).
21. Breiman L, Friedman J, Olshen R, Stone C: Classification and Regresston Tree. Chapman & Hall (Wadsworth, Inc.), New York, NY, USA (1984).
22. Cook NR, Zee RY, Ridker PM: Tree and spline based association analysis of gene-gene interaction models for ischemic stroke. Stat. Med. 23(9), 1439-1453 (2004).
23. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J. Gastroenterol. 9(6), 1144-1155 (2003).
24. Hull J, Thomson A, Kwiatkowski D: Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55, 1023-1027 (2000).
25. Mulder WM, Stern PL, Stukart MJ et al.: Low intercellular adhesion molecule 1 and high 5T4 expression of tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin. Cancer Res. 3, 1923-1930 (1997).
26. Vora DK, Rosenbloom CL, Beaudet AL et al.: Polymorphisms and linkage analysis for ICAM-1 and the selectin gene cluster. Genomics 21, 473-477 (1994).
27. Elliott RL, Blobe GC: Role of transforming growth factor β in human cancer. J. Clin. Onc. 23(9), 2078-2093 (2005).
28. Yokota M, Sahoko I, Tong-Lang L et al.: Association of a T29→C polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101, 2783-2787 (2000).
29. Tsushima H, Kawata S, Tamura S et al.: High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110, 375-382 (1996).
30. Friedman E, Gold LI, Klimstra D et al.: High levels of transforming growth factor β1 correlate with disease progression in human colon cancer. Cancer Epidemiol. Biomarkers Prev. 4(5), 549-554 (1995).
31. Solomon E, Voss R, Hall V et al.: Chromosome 5 allele loss in human colorectal carcinomas. Nature 328(6131), 616-619 (1987).
32. Losi L, Baisse B, Bouzourene H et al.: Evolution of intratumoral genetic heterogeneity during colorectal cancer. progression. Carcinogenesis 26(5), 916-922 (2005).
33. Horie N, Aiba H, Oguro K et al.: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20, 191-197 (1995).
34. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63, 2898-2904 (2003).
35. Ulrich CM, Bigler J, Velicer CM et al.: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9, 1381-1385 (2000).
36. Arand M, Muhlbauer R, Hengstler J et al.: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 236, 184-186 (1996).
37. Harries LW, Stubbins MJ, Forman D et al.: Identification of genetic polymorphisms at the glutathione S-transferase π locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18, 641-644 (1997).
38. Park DJ, Zhang W, Stoehlmacher J et al.: ERCC1 gene polymorphism as a predictor for clinical outcome in adyanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol. 1, 162-166 (2003).
39. Matullo G, Guarrera S, Carturan S et al.: DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int. J. Cancer 92, 562-567 (2001).
40. Hu JJ, Smith TR, Miller MS et al.: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917-922 (2001).
41. Levy-Lahad E, Lahad A, Eisenberg S et al.: A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl Acad. Sci. USA 98, 3232-3236 (2001).
42. Gnasso A, Motti C, Irace C et al.: Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler. Thromb. Vasc Biol. 20, 1600-1605 (2000).
43. Renner W, Kotschan S, Hoffmann C et al.: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37, 443-448 (2000).
44. Ziv E, Cauley J, Morin PA et al. Association between the T29>C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 285, 2859-2863 (2001).
45. Edwards-Smith CJ, Jonsson JR, Purdle DM et al.: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon α. Hepatology 30, 526-530 (1999).
46. Papafili A, Hill MR, Brull Dj et al.: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol. 22, 1631-1636 (2002).
47. Matsuzawa J, Sugimura K, Matsuda Y et al.: Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut 52, 75-78 (2003).
48. Biros E, Kalina I, Kohut A et al.: Germline polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 31, 157-162 (2001).
49. Henner WD, Evans AJ, Hough KM et al.: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 49, 263-266 (2001).
50. Betticher DC, Thatcher N, Altermatt HJ et al.: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011 (1995).
51. Steinberg D, Colla P: CART. Tree-Structured Non-Parametric Data Analysis. Salford Systems, CA, USA (1995).